Eli Lilly to Acquire Versanis for ~$1.92B
Shots:
- Versanis shareholders will receive ~$1.925B in cash incl. up front & subsequent fees upon achievement of development & sales milestones
- Versanis' bimagrumab, a mAb that binds activin type II A & B receptors to block activin & myostatin signaling is currently being evaluated in the P-IIb trial (BELIEVE) as monotx. & in combination with semaglutide for adults who are overweight or obese. The results are expected in the middle of 2024
- The acquisition focuses to expand Eli Lilly’s weight loss treatment portfolio & improves patient outcomes in cardiometabolic diseases. Bimagrumab & incretins have the potential to reduce fat mass while maintaining muscle mass which improves outcomes for persons with obesity & obesity-related complications
Ref: PR Newswire | Image: Eli Lilly
Related News:- Eli Lilly to Acquire DICE Therapeutics for ~$2.4B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
